Kidney Cancer Clinical Trial

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Summary

Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.

View Full Description

Full Description

This is a Phase 1, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors with varying degrees of renal impairment. The study is conducted in 2 parts: the Pharmacokinetic Part (Cycle 1) and the Extension Part (Cycles 2 and beyond). Patients may continue to receive treatment with TAS-102 during the study extension part only after completion of the Pharmacokinetic Part.

View Eligibility Criteria

Eligibility Criteria

Inclusion

Has provided written informed consent
Has advanced solid tumors (excluding breast cancer)
Has normal renal function, mild, moderate, or severe renal impairment and is not on dialysis
ECOG performance status of ≤2
Is able to take medications orally
Has adequate organ function
Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.

Exclusion

Certain serious illnesses or medical condition(s)
Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration
Has received TAS-102
Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies
Is a pregnant or lactating female

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

43

Study ID:

NCT02301117

Recruitment Status:

Completed

Sponsor:

Taiho Oncology, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 12 Locations for this study

See Locations Near You

Phoenix Clinical Site
Phoenix Arizona, 85054, United States
Duarte Clinical Site
Duarte California, 91010, United States
Santa Monica Clinical Site
Santa Monica California, 90095, United States
Gainesville Clinical Site
Gainesville Florida, 32610, United States
Baltimore Clinical Site
Baltimore Maryland, 21231, United States
Boston Clinical Site
Boston Massachusetts, 02111, United States
Cleveland Clinical Site
Cleveland Ohio, 44106, United States
Cleveland Clinical Site
Cleveland Ohio, 44195, United States
Pittsburgh Clinical Site
Pittsburgh Pennsylvania, 15232, United States
Dallas Clinical Site
Dallas Texas, 75246, United States
Brno Clinical Site
Brno , , Czechia
Praha Clinical Site
Praha , , Czechia
Belgrade Clinical Site
Belgrade , 11080, Serbia
Sremska Kamenica Clinical Site
Sremska Kamenica , 21204, Serbia

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

43

Study ID:

NCT02301117

Recruitment Status:

Completed

Sponsor:


Taiho Oncology, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider